Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

OBJECTIVE: The increased risk of progressive multifocal leukoencephalopathy (PML) with natalizumab treatment is associated with the presence of anti–JC virus (JCV) antibodies. We analyzed whether anti-JCV antibody levels, measured as index, may further define PML risk in seropositive patients. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Plavina, Tatiana, Subramanyam, Meena, Bloomgren, Gary, Richman, Sandra, Pace, Amy, Lee, Sophia, Schlain, Brian, Campagnolo, Denise, Belachew, Shibeshih, Ticho, Barry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282070/
https://www.ncbi.nlm.nih.gov/pubmed/25273271
http://dx.doi.org/10.1002/ana.24286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282070/
https://www.ncbi.nlm.nih.gov/pubmed/25273271
http://dx.doi.org/10.1002/ana.24286

Ejemplares similares